Based on clinical trial data, tirzepatide generally produces lower rates of gastrointestinal side effects at weight loss doses despite causing greater weight loss
Il est trs abondant dans le foie, le cerveau, le coeur et les reins
Brain Behav Immun 55:8292 Shan Y, Tan S, Lin Y, Liao S, Zhang B, Chen X, Wang J, Deng Z, Zeng Q, Zhang L, Wang Y, Hu XQ, Qiu W, Peng L, Lu ZQ (2019) The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke
The cardiac benefits of GLP-1 agonists were not anticipated before outcome studies were performed for several reasons: (1) Historical Precedent-past experiences with other diabetes medications that unexpectedly had adverse cardiovascular effects made it less likely for researchers and clinicians to anticipate potential cardiovascular benefits without concrete evidence from large-scale trials
Macrophage-adipocyte co-culture Macrophage-adipocyte co-culture was performed as described previously [39]
